Amyloid Neuropathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major amyloid neuropathies markets are expected to exhibit a CAGR of 4.8% during 2024-2034
The amyloid neuropathies market has been comprehensively analyzed in IMARC's new report titled "Amyloid Neuropathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Amyloid neuropathies are a group of neurological disorders characterized by the deposition of irregular protein aggregates, called amyloid, within peripheral nerves. This disease can lead to nerve damage and dysfunction, resulting in a range of debilitating symptoms. Common indications of the ailment include sensory disturbances, such as tingling, numbness, and burning sensations in the extremities, muscle weakness, and impaired coordination. Pain, especially in the limbs, and autonomic dysfunction, manifesting as changes in blood pressure, heart rate, and digestion, are also frequent features. The diagnosis of amyloid neuropathies typically involves a combination of clinical assessment, nerve conduction studies, and nerve biopsies. The identification of amyloid deposits within nerve tissue through a biopsy is crucial for confirming the diagnosis. Additionally, advanced imaging techniques like MRI can aid in evaluating nerve damage and the distribution of amyloid deposits. Distinguishing the specific type of amyloid involved is essential, as treatment approaches may vary depending on the underlying cause.
The escalating incidences of genetic mutations that cause the protein to misfold and aggregate into amyloid deposits, which accumulate in various tissues, including nerves, are primarily driving the amyloid neuropathies market. In addition to this, the inflating utilization of efficacious treatments like monoclonal antibodies, proteostasis modulators, and gene-silencing therapies aimed at mitigating symptoms and halting disease progression is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies, such as pain management strategies, physical rehabilitation, and targeted interventions to address specific indications associated with the condition, is further bolstering the market growth. Apart from this, the rising usage of novel technologies like RNA interference, which enables the selective suppression of the genes responsible for abnormal protein production, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of physical and rehabilitative therapies, since they are designed to improve muscle strength, balance, and functional autonomy, is also augmenting the market growth. Furthermore, the increasing R&D activities to launch novel therapies like antisense oligonucleotides that target the underlying genetic mechanisms, thereby offering potential curative interventions with greater efficacy and reduced side effects, are expected to drive the amyloid neuropathies market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the amyloid neuropathies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for amyloid neuropathies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the amyloid neuropathies market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the amyloid neuropathies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the amyloid neuropathies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current amyloid neuropathies marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the amyloid neuropathies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the amyloid neuropathies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the amyloid neuropathies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of amyloid neuropathies across the seven major markets?
What is the number of prevalent cases (2018-2034) of amyloid neuropathies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of amyloid neuropathies by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with amyloid neuropathies across the seven major markets?
What is the size of the amyloid neuropathies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of amyloid neuropathies?
What will be the growth rate of patients across the seven major markets?
Amyloid Neuropathies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for amyloid neuropathies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the amyloid neuropathies market?
What are the key regulatory events related to the amyloid neuropathies market?
What is the structure of clinical trial landscape by status related to the amyloid neuropathies market?
What is the structure of clinical trial landscape by phase related to the amyloid neuropathies market?
What is the structure of clinical trial landscape by route of administration related to the amyloid neuropathies market?
The amyloid neuropathies market has been comprehensively analyzed in IMARC's new report titled "Amyloid Neuropathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Amyloid neuropathies are a group of neurological disorders characterized by the deposition of irregular protein aggregates, called amyloid, within peripheral nerves. This disease can lead to nerve damage and dysfunction, resulting in a range of debilitating symptoms. Common indications of the ailment include sensory disturbances, such as tingling, numbness, and burning sensations in the extremities, muscle weakness, and impaired coordination. Pain, especially in the limbs, and autonomic dysfunction, manifesting as changes in blood pressure, heart rate, and digestion, are also frequent features. The diagnosis of amyloid neuropathies typically involves a combination of clinical assessment, nerve conduction studies, and nerve biopsies. The identification of amyloid deposits within nerve tissue through a biopsy is crucial for confirming the diagnosis. Additionally, advanced imaging techniques like MRI can aid in evaluating nerve damage and the distribution of amyloid deposits. Distinguishing the specific type of amyloid involved is essential, as treatment approaches may vary depending on the underlying cause.
The escalating incidences of genetic mutations that cause the protein to misfold and aggregate into amyloid deposits, which accumulate in various tissues, including nerves, are primarily driving the amyloid neuropathies market. In addition to this, the inflating utilization of efficacious treatments like monoclonal antibodies, proteostasis modulators, and gene-silencing therapies aimed at mitigating symptoms and halting disease progression is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies, such as pain management strategies, physical rehabilitation, and targeted interventions to address specific indications associated with the condition, is further bolstering the market growth. Apart from this, the rising usage of novel technologies like RNA interference, which enables the selective suppression of the genes responsible for abnormal protein production, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of physical and rehabilitative therapies, since they are designed to improve muscle strength, balance, and functional autonomy, is also augmenting the market growth. Furthermore, the increasing R&D activities to launch novel therapies like antisense oligonucleotides that target the underlying genetic mechanisms, thereby offering potential curative interventions with greater efficacy and reduced side effects, are expected to drive the amyloid neuropathies market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the amyloid neuropathies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for amyloid neuropathies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the amyloid neuropathies market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the amyloid neuropathies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the amyloid neuropathies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current amyloid neuropathies marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the amyloid neuropathies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the amyloid neuropathies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the amyloid neuropathies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of amyloid neuropathies across the seven major markets?
What is the number of prevalent cases (2018-2034) of amyloid neuropathies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of amyloid neuropathies by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with amyloid neuropathies across the seven major markets?
What is the size of the amyloid neuropathies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of amyloid neuropathies?
What will be the growth rate of patients across the seven major markets?
Amyloid Neuropathies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for amyloid neuropathies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the amyloid neuropathies market?
What are the key regulatory events related to the amyloid neuropathies market?
What is the structure of clinical trial landscape by status related to the amyloid neuropathies market?
What is the structure of clinical trial landscape by phase related to the amyloid neuropathies market?
What is the structure of clinical trial landscape by route of administration related to the amyloid neuropathies market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AMYLOID NEUROPATHIES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AMYLOID NEUROPATHIES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AMYLOID NEUROPATHIES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 AMYLOID NEUROPATHIES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AMYLOID NEUROPATHIES - UNMET NEEDS
10 AMYLOID NEUROPATHIES - KEY ENDPOINTS OF TREATMENT
11 AMYLOID NEUROPATHIES - MARKETED PRODUCTS
11.1 List of Amyloid Neuropathies Marketed Drugs Across the Top 7 Markets
11.1.1 Amvuttra (Vutrisiran) - Alnylam Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Onpattro (Patisiran) - Alnylam Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Tegsedi (Inotersen) - Akcea Therapeutics
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Vyndaqel(Tafamidis) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AMYLOID NEUROPATHIES - PIPELINE DRUGS
12.1 List of Amyloid Neuropathies Pipeline Drugs Across the Top 7 Markets
12.1.1 Eplontersen - Ionis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NTLA-2001 - Intellia Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. AMYLOID NEUROPATHIES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AMYLOID NEUROPATHIES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AMYLOID NEUROPATHIES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Amyloid Neuropathies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Amyloid Neuropathies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Amyloid Neuropathies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Amyloid Neuropathies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Amyloid Neuropathies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Amyloid Neuropathies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Amyloid Neuropathies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Amyloid Neuropathies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Amyloid Neuropathies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Amyloid Neuropathies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Amyloid Neuropathies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Amyloid Neuropathies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Amyloid Neuropathies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Amyloid Neuropathies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Amyloid Neuropathies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Amyloid Neuropathies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Amyloid Neuropathies - Access and Reimbursement Overview
16 AMYLOID NEUROPATHIES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AMYLOID NEUROPATHIES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AMYLOID NEUROPATHIES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AMYLOID NEUROPATHIES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AMYLOID NEUROPATHIES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AMYLOID NEUROPATHIES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 AMYLOID NEUROPATHIES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AMYLOID NEUROPATHIES - UNMET NEEDS
10 AMYLOID NEUROPATHIES - KEY ENDPOINTS OF TREATMENT
11 AMYLOID NEUROPATHIES - MARKETED PRODUCTS
11.1 List of Amyloid Neuropathies Marketed Drugs Across the Top 7 Markets
11.1.1 Amvuttra (Vutrisiran) - Alnylam Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Onpattro (Patisiran) - Alnylam Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Tegsedi (Inotersen) - Akcea Therapeutics
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Vyndaqel(Tafamidis) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AMYLOID NEUROPATHIES - PIPELINE DRUGS
12.1 List of Amyloid Neuropathies Pipeline Drugs Across the Top 7 Markets
12.1.1 Eplontersen - Ionis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NTLA-2001 - Intellia Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. AMYLOID NEUROPATHIES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AMYLOID NEUROPATHIES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AMYLOID NEUROPATHIES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Amyloid Neuropathies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Amyloid Neuropathies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Amyloid Neuropathies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Amyloid Neuropathies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Amyloid Neuropathies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Amyloid Neuropathies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Amyloid Neuropathies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Amyloid Neuropathies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Amyloid Neuropathies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Amyloid Neuropathies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Amyloid Neuropathies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Amyloid Neuropathies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Amyloid Neuropathies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Amyloid Neuropathies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Amyloid Neuropathies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Amyloid Neuropathies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Amyloid Neuropathies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Amyloid Neuropathies - Access and Reimbursement Overview
16 AMYLOID NEUROPATHIES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AMYLOID NEUROPATHIES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AMYLOID NEUROPATHIES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
